Compare Abeona Therapeutics Inc (ABEO) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Inovio Pharmaceuticals Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Inovio Pharmaceuticals Inc trades at $1.22 (market cap $99.55M). The key difference: Abeona Therapeutics Inc is far larger — about 3.8× Inovio Pharmaceuticals Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | INO | |
|---|---|---|
Market Cap | $373.32M | $99.55M |
Sector | Health | Health |
52-Week High | $7.23 | $2.87 |
52-Week Low | $4.17 | $1.05 |
Enterprise Value | $228.22M | $70.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
INO trades at $1.21, down 2.02% today, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company shows minimal revenue of $65,340 (2025) with significant losses (-$84.95M net income), though recent earnings beats and FDA review of INO-3107 (PDUFA date October 30, 2026) provide catalysts. Analyst consensus is 53% buy, but multiple class action lawsuits pose legal risks.
Outlook hinges on FDA approval of INO-3107, which could drive upside, but high cash burn (-$21.54M net cash flow in 2025) and negative margins (-130,000% net income margin) underscore substantial operational risks. Investors face a binary event-driven opportunity with elevated volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
